Page last updated: 2024-11-12

aramchol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID18738120
CHEMBL ID4297262
SCHEMBL ID548961
MeSH IDM0425167

Synonyms (35)

Synonym
arachidyl
unii-qe1q24m65y
aramchol ,
246529-22-6
qe1q24m65y ,
(3beta,5beta,7alpha,12alpha)-7,12-dihydroxy-3-(icosanoylamino)cholan-24-oic acid
r20-fbac
arachidyl amido cholanoic acid
(3.beta.)-arachidylamido-7.alpha.,12.alpha.-dihydroxy-5.beta.-cholan-24-oic acid
arachidyl amido cholanoic acid [who-dd]
c20-fabac
icomidocholic acid
cholan-24-oic acid, 7,12-dihydroxy-3-((1-oxoeicosyl)amino)-, (3.beta.,5.beta.,7.alpha.,12.alpha.)-
icomidocholic acid [inn]
SHKXZIQNFMOPBS-OOMQYRRCSA-N
3beta-arachidylamido-7alpha,12alpha-dihydroxy-5beta-cholan-24-oic acid
SCHEMBL548961
AC-30875
DTXSID90179395
amido cholanoic acid,
DB11860
HY-19796
CS-0016645
Q27287206
A903776
(4r)-4-[(3s,5s,7r,8r,9s,10s,12s,13r,14s,17r)-7,12-dihydroxy-3-(icosanoylamino)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoic acid
EX-A4308
F82084
(3beta,5beta,7alpha12alpha)-7,12-dihydroxy-3-[(1-oxoeicosyl)amino]cholan-24-oic acid
MS-31168
CHEMBL4297262
(r)-4-((3s,5s,7r,8r,9s,10s,12s,13r,14s,17r)-7,12-dihydroxy-3-icosanamido-10,13-dimethylhexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanoic acid
WJA52922
GLXC-26805
AKOS040759104

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The same phenomenon was demonstrated in human bile ex vivo, with a dose-response effect."( Arachidyl amido cholanoic acid (Aramchol) is a cholesterol solubilizer and prevents the formation of cholesterol gallstones in inbred mice.
Gilat, T; Goldiner, L; Halpern, Z; Konikoff, FM; Laufer, H; Leikin-Frenkel, A, 2001
)
0.59
"35), indicating a dose-response relationship (P for trend = ."( The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease.
Gilat, T; Halpern, M; Konikoff, FM; Mahamid, M; Oren, R; Safadi, R; Zelber-Sagi, S, 2014
)
0.68
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (46.67)29.6817
2010's5 (33.33)24.3611
2020's3 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.42

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.42 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index4.50 (4.65)
Search Engine Demand Index49.68 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.42)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (20.00%)5.53%
Reviews3 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (60.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]